Endra Life Sciences Inc Expected To Post A Loss Of $4.08 A Share: Earnings Preview
09/05/2025 13:32
ENDRA Life Sciences Inc NDRA.OQ NDRA.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for ENDRA Life Sciences Inc is for a loss of $4.08 per share. The one available analyst rating on the shares is "buy". The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $75.00, above its last closing price of $6.15. This summary was machine generated May 9 at 12:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on ENDRA Life Sciences
See all newsBrief: ENDRA Life Sciences - Enters First Amendment To Merger Agreement On October 1, 2026 - SEC Filing
ENDRA Life Sciences posts Q2 profit on digital asset gains ahead of merger
Endra Life Sciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Endra Life Sciences Inc Expected To Post A Loss Of 84 Cents A Share: Earnings Preview
Brief: ASP Isotopes Announces Proposed Merger Of Noble Africa With Endra Life Sciences